Hims & Hers Health, Inc. Class A Common Stock (HIMS)
58.40
+3.53 (6.43%)
NYSE · Last Trade: Sep 28th, 11:12 AM EDT
Detailed Quote
Previous Close
54.87
Open
54.40
Bid
58.17
Ask
58.35
Day's Range
54.11 - 58.40
52 Week Range
16.05 - 72.98
Volume
27,414,797
Market Cap
11.21B
PE Ratio (TTM)
73.92
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
28,344,450
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2% in the morning session after an insider filed to sell a substantial block of shares.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.5% in the morning session after investors focused on the company's strong growth prospects, which appeared to overshadow recent regulatory challenges.
Oscar Health (OSCR) is drawing comparisons to Hims & Hers (HIMS) as short sellers may trigger a moonshot with ACA subsidies and a potential government shutdown.
US markets closed slightly lower on Tuesday as investors waited for the Fed’s rate decision. Strong retail sales weren’t enough to lift the market, while several standout stock moves, from Steel Dynamics’ profit surprise to a sharp FDA blow for Hims & Hers, dominated the headlines.
A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one thing is certain; after a year of tech-led mega caps setting new highs, investors have clearly shown an increased appetite for risk in the form of smaller, lesser known names.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) sent the company a warning letter regarding “false or misleading” claims about its compounded semaglutide products.
